RecruitingPhase 1NCT06482190

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shenzhen Resproly Biopharmaceutical Co., Ltd
Intervention
RSN0402 Part 1(drug)
Enrollment
72 enrolled
Eligibility
18-60 years · All sexes
Timeline
2024 – 2025

Study locations (3)

Collaborators

Resproly Australia Pty Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06482190 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials